Follow
Marc A Pfeffer
Marc A Pfeffer
Professor, Harvard Medical School, Brigham and Women's Hospital
Verified email at rics.bwh.harvard.edu
Title
Cited by
Cited by
Year
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
47471*2017
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
FM Sacks, MA Pfeffer, LA Moye, JL Rouleau, JD Rutherford, TG Cole, ...
New England Journal of Medicine 335 (14), 1001-1009, 1996
100191996
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on …
RA Nishimura, CM Otto, RO Bonow, BA Carabello, JP Erwin III, ...
Circulation 129 (23), e521-e643, 2014
9350*2014
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial
MA Pfeffer, E Braunwald, LA Moyé, L Basta, EJ Brown Jr, TE Cuddy, ...
New England journal of medicine 327 (10), 669-677, 1992
75731992
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
DC Goff Jr, DM Lloyd-Jones, G Bennett, S Coady, RB D’agostino, ...
Circulation 129 (25_suppl_2), S49-S73, 2014
69502014
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon, E Braunwald, CH McCabe, DJ Rader, JL Rouleau, R Belder, ...
New England journal of medicine 350 (15), 1495-1504, 2004
65722004
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High …
MJ Sarnak, AS Levey, AC Schoolwerth, J Coresh, B Culleton, LL Hamm, ...
Circulation 108 (17), 2154-2169, 2003
57362003
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
MA Pfeffer, E Braunwald
Circulation 81 (4), 1161-1172, 1990
43511990
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
S Yusuf, MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ...
The Lancet 362 (9386), 777-781, 2003
37342003
Cardiac-resynchronization therapy for the prevention of heart-failure events
AJ Moss, WJ Hall, DS Cannom, H Klein, MW Brown, JP Daubert, ...
New England Journal of Medicine 361 (14), 1329-1338, 2009
35472009
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
MA Pfeffer, JJV McMurray, EJ Velazquez, JL Rouleau, L Køber, ...
New England Journal of Medicine 349 (20), 1893-1906, 2003
33222003
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood …
SC Smith Jr, J Allen, SN Blair, RO Bonow, LM Brass, GC Fonarow, ...
Circulation 113 (19), 2363-2372, 2006
31092006
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
F Turnbull, B Neal, C Algert, J Chalmers, M Woodward, S MacMahon, ...
Lancet 362 (9395), 1527-1535, 2003
31042003
Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19
M Vaduganathan, O Vardeny, T Michel, JJV McMurray, MA Pfeffer, ...
New England Journal of Medicine 382 (17), 1653-1659, 2020
26762020
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
JJV McMurray, J Östergren, K Swedberg, CB Granger, P Held, ...
The Lancet 362 (9386), 767-771, 2003
26582003
C-reactive protein levels and outcomes after statin therapy
PM Ridker, CP Cannon, D Morrow, N Rifai, LM Rose, CH McCabe, ...
New England Journal of Medicine 352 (1), 20-28, 2005
26142005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon, JJV McMurray, MA Pfeffer, J Wittes, R Fowler, P Finn, ...
New England Journal of Medicine 352 (11), 1071-1080, 2005
25992005
Spironolactone for heart failure with preserved ejection fraction
B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ...
New England Journal of Medicine 370 (15), 1383-1392, 2014
25942014
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM …
CB Granger, JJV McMurray, S Yusuf, P Held, EL Michelson, B Olofsson, ...
The Lancet 362 (9386), 772-776, 2003
25672003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ...
The Lancet 362 (9386), 759-766, 2003
25462003
The system can't perform the operation now. Try again later.
Articles 1–20